Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: valacyclovir hydrochloride Clear all
Completed Phase 2 Interventional Results available

Valacyclovir for Mild Cognitive Impairment

NCT04710030
View directory record Official record
Conditions
Mild Cognitive Impairment, Herpes Simplex 1, Herpes Simplex 2
Interventions
Valacyclovir hydrochloride 500mg caplet, Placebo sugar pill caplet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions

NCT01132729
View directory record Official record
Conditions
Herpes Zoster, Shingles, Genital Herpes
Interventions
Valacyclovir Hydrochloride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

NCT01972035
View directory record Official record
Conditions
Transplantation Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections
Interventions
Valacyclovir, Valganciclovir
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

NCT03131037
View directory record Official record
Conditions
Lung Cancer
Interventions
CAN-2409 + valacyclovir
Biological
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

NCT00589875
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
Interventions
CAN-2409, Valacyclovir, Temozolomide, Radiation therapy
Biological · Drug · Radiation
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 21, 2026, 8:03 AM EDT
Recruiting Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

NCT02008773
View directory record Official record
Conditions
Schizophrenia
Interventions
Valacyclovir HCI 500 mg tablets, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Bellflower, California • Los Angeles, California • Riverside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 21, 2026, 8:03 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Valacyclovir in Pain Management of Acute Apical Abscesses

NCT05266040
View directory record Official record
Conditions
Acute Apical Abscess, Pain, Acute
Interventions
Valacyclovir 500 MG, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 21, 2026, 8:03 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis

NCT05712343
View directory record Official record
Conditions
Severe Periodontitis
Interventions
Valacyclovir group, Control group
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition

NCT04640571
View directory record Official record
Conditions
Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80
Interventions
pravastatin and chenodeoxycholic acid, after metformin and placebo, valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 3 Interventional

Valaciclovir to Prevent Transmission of Herpes Simplex Virus

NCT00001649
View directory record Official record
Conditions
Herpes Simplex
Interventions
Valaciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 3 Interventional

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

NCT00001038
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 21, 2026, 8:03 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

NCT02831933
View directory record Official record
Conditions
Lung Squamous Cell Carcinoma Stage IV, Nonsquamous Nonsmall Cell Neoplasm of Lung, Metastatic Uveal Melanoma
Interventions
ADV/HSV-tk, Valacyclovir, SBRT, nivolumab
Biological · Drug · Radiation
Lead sponsor
Eric Bernicker, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Not applicable Interventional

Reduction of Postherpetic Neuralgia in Herpes Zoster

NCT01250561
View directory record Official record
Conditions
Herpes Zoster, Post-herpetic Neuralgia
Interventions
Gabapentin, Valacyclovir
Drug
Lead sponsor
Center for Clinical Studies, Texas
Other
Eligibility
50 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 21, 2026, 8:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

NCT07346144
View directory record Official record
Conditions
Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
TGX-007, Valaciclovir
Drug
Lead sponsor
Trogenix ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 8:03 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers

NCT00587496
View directory record Official record
Conditions
Herpes Simplex
Interventions
valacyclovir hydrochloride, placebo, valacyclovir plus aspirin
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
20 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 1Phase 2 Interventional

Controlled Trial of Valacyclovir in Infectious Mononucleosis

NCT00274404
View directory record Official record
Conditions
Infectious Mononucleosis
Interventions
valacyclovir
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 21, 2026, 8:03 AM EDT
Recruiting Phase 2 Interventional

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

NCT07332000
View directory record Official record
Conditions
Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Interventions
aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT)
Biological · Radiation
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Peoria, Arizona • Lakewood, Colorado • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir

NCT00031486
View directory record Official record
Conditions
Encephalitis
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas

NCT00751270
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
AdV-tk, Valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma

NCT01811992
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme
Interventions
Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L
Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 8:03 AM EDT
Not listed Phase 2 Interventional

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

NCT00652184
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir
Drug
Lead sponsor
aRigen Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Beverly Hills, California • Encino, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 21, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

NCT00306293
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
18
States / cities
Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 21, 2026, 8:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers

NCT00870441
View directory record Official record
Conditions
Safety of ASP2151
Interventions
ASP2151, Valacyclovir, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
442 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Daytona Beach, Florida • Honolulu, Hawaii • Evansville, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 21, 2026, 8:03 AM EDT